查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857955

恶性间皮癌市场按治疗类型、药物类别、治疗线、给药途径和最终用户划分－2025-2032年全球预测

Malignant Mesothelioma Market by Treatment Type, Drug Class, Line Of Therapy, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，恶性间皮癌市场规模将成长 16.0715 亿美元，复合年增长率为 8.53%。

关键市场统计数据
基准年 2024 8.3443亿美元
预计年份：2025年 9.0516亿美元
预测年份 2032 16.0715亿美元
复合年增长率 (%) 8.53%

本书权威地介绍了恶性间皮癌，涵盖其临床负担、诊断复杂性、不断发展的多学科治疗路径以及临床和商业性决策的战略要务。

恶性间皮癌是一种复杂的肿瘤，其特征是发病较晚、组织学异质性强，且对临床治疗和患者生活品质有显着影响。诊断流程越来越依赖影像学、病理学和分子谱分析的整合，以区分组织学亚型并识别可靶向的治疗靶点；同时，多学科肿瘤委员会在将治疗方案与患者的功能状态和偏好相匹配方面发挥关键作用。

儘管系统性疗法和外科技术的进步拓展了临床应用途径，但要显着改善长期疗效，需要在诊断、治疗研发和治疗实施等各个环节协调推进。因此，临床医生、生物製药研发人员和支付方必须应对不断更新的证据、不断变化的监管预期以及证明真实世界疗效的压力。本导言透过阐明疾病背景、关键临床挑战以及影响研发投入和商业化策略的策略要务，为后续分析组装。

整份报告都着重强调将临床见解转化为营运重点。早期准确诊断、将未满足的需求与临床试验设计相匹配，并将患者报告结果整合到研发项目中，被强调为改善治疗的关键途径。透过将读者置于这一临床和商业性环境中，引言部分为在研发和上市等各个环节做出明智的决策奠定了基础。

对再形成间皮瘤治疗的变革性转变进行全面回顾，包括免疫肿瘤学突破、精准标靶药物、监管动态、支付方准入动态以及研发优先事项。

间皮瘤的监管格局正经历着一场变革性的转变，其驱动力包括科学突破、监管调整以及支付方和医疗服务提供者期望的改变。免疫肿瘤疗法在部分患者中展现出持久疗效，正在重塑治疗模式，促使人们重新思考治疗顺序和合併治疗策略。同时，利用肿瘤特异性生物标记的标靶治疗正在再形成临床研发的重点，并推动在诊断时进行更深入的分子特征分析。

监管机构越来越接受适应性开发路径和真实世界证据来支持核准和标籤决定，这加快了有前景的治疗方法惠及患者的速度，但也提高了核准后证据生成的标准。同时，支付方和提供方利益相关人员要求透过比较疗效、以患者为中心的结果以及考虑医疗保健成本来更清晰地证明价值，这正在影响试验设计和打入市场策略。

在营运层面，这项转变需要更整合的转换流程、更早与监管机构和医疗照护机构接洽，以及加强学术中心、生技公司和社区医疗机构之间的合作。更精细的诊断分层、联合治疗的探索以及对生存率和支持性治疗指标的更关注，将成为下一波进展的特征。因此，相关人员必须调整经营模式，以支持适应性试验、灵活的商业策略以及超越传统随机对照试验终点的可靠证据生成。

重点分析美国关税在2025年对间皮瘤药物供应链、临床应用、研究合作、生产成本和商业营运的累积影响

美国将于2025年实施关税调整，这将对全球药品供应链、临床准入途径以及与间皮瘤治疗相关的合作研究计画产生复杂的影响。这些措施将影响进口活性药物原料药、专用设备和辅助用品的成本基础，进而可能影响跨国研发企业和契约製造的生产策略和库存管理。

临床上，供应中断和成本上涨可能会对高成本疗法造成分配压力，并影响医疗机构的处方决策。支付方和医疗服务提供者可能会寻求更严格的采购要求，尽可能优先选择国产产品，或寻求更高的价格透明度和基于疗效的合约模式，以维持患者的可及性。此外，跨国合作也可能面临行政方面的摩擦，因为关税相关的成本会改变预算预测，并使国际合作伙伴之间的物资转移安排变得复杂。

在营运方面，生物製药公司正在透过重新评估供应商多元化、在经济可行的情况下将关键生产流程迁回国内以及谈判长期采购协议来应对市场波动。同时，监管和合规团队正在调整合约和品质保证流程，以适应不断变化的贸易措施。总而言之，这些调整表明，即使在贸易政策变化时期，也需要製定整合的商业、供应链和临床策略，以维持治疗药物的供应并优先保障患者的用药权。

基于细分市场的洞察揭示了治疗方式、药物类别、治疗线、给药途径和最终用户等因素如何影响研发重点和病患路径。

细分市场分析揭示了不同的临床和商业因素如何相互作用，从而影响投资重点和患者治疗路径。基于治疗类型，本研究对化疗、免疫疗法、放射线治疗、手术和标靶治疗市场进行了分析。化疗方面，我们将进一步探讨Pemetrexed塞联合治疗疗法和铂类单药疗法。免疫疗法方面，我们将进一步探讨 CtLA-4 抑制剂和 PD-1 抑制剂。在标靶治疗，我们将进一步探讨 EGFR 抑制剂、间皮素标靶药物和 VEGF 抑制剂。了解这些治疗方式之间的差异，将有助于我们预测创新药物的涌现方向，以及哪些临床族群将从新的联合疗法中获益更多。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新型免疫疗法联合治疗显示恶性间皮癌患者存活期延长。
  • 在后期临床试验中采用间皮素标靶抗体药物复合体
  • 利用基因组分析的间皮瘤个人化治疗策略正在兴起
  • 一线间皮瘤治疗方法中双重查核点抑制剂的使用日益增多
  • 扩大间皮素标靶CAR-T细胞疗法在间皮瘤治疗的应用范围
  • 人们对间皮瘤早期诊断生物标记和液态切片技术的兴趣日益浓厚
  • 动态疗法在不可切除癌症治疗的进展：恶性间皮癌
  • 制定整合手术、放射线治疗和全身性治疗的多学科治疗通讯协定
  • 提高对石棉暴露诉讼对间皮瘤患者登记册影响的认识
  • 扩大真实世界证据资料集，为治疗指引和健保报销提供依据

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章恶性间皮癌市场依治疗类型划分

  • 化疗
    • Pemetrexed组合
    • 铂类单药治疗
  • 免疫疗法
    • Ctla-4抑制剂
    • Pd-1抑制剂
  • 放射线治疗
  • 手术治疗
  • 标靶治疗
    • EGFR抑制剂
    • 间皮素标靶药物
    • Vegf抑制剂

第九章恶性间皮癌药物市场

  • 抗叶酸
  • 免疫查核点抑制剂
    • Ctla-4抑制剂
    • Pd-1抑制剂
    • Pd-l1抑制剂
  • 激酶抑制剂
  • 单株抗体
  • 铂化合物

第十章恶性间皮癌市场（依治疗线划分）

  • 一线
  • 第二行
  • 三线及以后

第十一章恶性间皮癌市场依给药途径划分

  • 腹腔内
  • 静脉
  • 口服

第十二章恶性间皮癌市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章恶性间皮癌市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章恶性间皮癌市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国恶性间皮癌市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Johnson & Johnson
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Sanofi SA
Product Code: MRR-C002B1C99564

The Malignant Mesothelioma Market is projected to grow by USD 1,607.15 million at a CAGR of 8.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 834.43 million
Estimated Year [2025] USD 905.16 million
Forecast Year [2032] USD 1,607.15 million
CAGR (%) 8.53%

An authoritative introduction to malignant mesothelioma that frames clinical burden, diagnostic complexity, evolving multidisciplinary care pathways, and strategic imperatives for clinical and commercial decision-making

Malignant mesothelioma remains a complex oncologic entity characterized by late-stage presentation, histologic heterogeneity, and significant implications for clinical management and patient quality of life. Diagnostic pathways increasingly rely on integrated imaging, pathology, and molecular profiling to distinguish histologic subtypes and identify actionable targets, while multidisciplinary tumor boards play a pivotal role in aligning therapeutic intent with functional status and patient preferences.

Advances in systemic therapies and surgical techniques have expanded the clinical toolkit, yet meaningful improvement in long-term outcomes requires coordinated advances across diagnostics, therapeutic development, and care delivery. Consequently, clinicians, biopharma developers, and payers must navigate an environment of evolving evidence, shifting regulatory expectations, and pressure to demonstrate real-world effectiveness. This introduction frames the ensuing analysis by establishing the disease context, the principal clinical challenges, and the strategic imperatives that shape research investments and commercialization approaches.

Throughout the report, emphasis is placed on translating clinical insights into operational priorities. Early and accurate diagnosis, alignment of clinical trial design with unmet needs, and integration of patient-reported outcomes into development programs are highlighted as critical vectors for improving care. By situating the reader within this clinical and commercial landscape, the introduction provides the foundation required for informed decision-making across research, development, and market access functions.

A comprehensive review of the transformative shifts reshaping mesothelioma care, encompassing immuno-oncology breakthroughs, precision-targeted agents, regulatory momentum, payer access dynamics, and R&D prioritization

The mesothelioma landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory recalibration, and changing expectations from payers and providers. Immuno-oncology agents have reoriented therapeutic paradigms by demonstrating durable responses in subsets of patients, prompting reconsideration of sequencing and combination strategies. In parallel, targeted therapies that exploit tumor-specific biomarkers are reshaping clinical development priorities and encouraging more granular molecular characterization at diagnosis.

Regulatory bodies are increasingly receptive to adaptive development pathways and real-world evidence to support approval and labeling decisions, which accelerates time-to-patient for promising therapies but also raises the bar for post-approval evidence generation. Meanwhile, payer and provider stakeholders demand clearer demonstration of value through comparative effectiveness, patient-centric outcomes, and cost-of-care considerations, which in turn influences trial design and market access strategies.

Operationally, these shifts require more integrated translational pipelines, earlier engagement with regulatory and reimbursement authorities, and stronger alliances between academic centers, biotechnology firms, and community providers. Enhanced diagnostic stratification, combination modality research, and a focus on survivorship and supportive care metrics will be defining features of the next wave of progress. As a result, stakeholders must adapt business models to support adaptive trials, flexible commercial strategies, and robust evidence generation that extends beyond traditional randomized controlled trial endpoints.

A focused analysis of the cumulative impact of United States tariff measures in 2025 on mesothelioma therapeutic supply chains, clinical access, research collaborations, manufacturing costs, and commercial operations

The introduction of tariff adjustments in the United States during 2025 has created a complex set of implications for global pharmaceutical supply chains, clinical access pathways, and collaborative research programs that are relevant to mesothelioma therapies. These measures can influence the cost base for imported active pharmaceutical ingredients, specialized devices, and ancillary supplies, which, in turn, affect manufacturing strategies and inventory management across multinational developers and contract manufacturers.

Clinically, any supply disruption or cost escalation can translate into allocation pressures for high-cost therapies and influence institutional formulary decisions. Payers and providers may seek more stringent procurement terms, prioritize domestically sourced products where feasible, or request enhanced pricing transparency and outcomes-based contracting to preserve access. Moreover, cross-border research collaborations can face administrative friction if tariff-associated costs alter budget projections or complicate material transfer arrangements between international partners.

From an operational perspective, biopharma organizations are responding by reassessing supplier diversification, onshoring critical production steps where economically viable, and negotiating long-term procurement agreements to buffer volatility. Meanwhile, regulatory and compliance teams are aligning contracts and quality assurance processes to accommodate evolving trade measures. Taken together, these adjustments underscore the need for integrated commercial, supply chain, and clinical strategies to preserve therapy availability and ensure that patient access remains the guiding priority during periods of trade policy change.

Insightful segmentation-driven perspectives revealing how treatment modality, drug class, line of therapy, route of administration, and end-user dynamics collectively define development priorities and patient care pathways

Segmentation analysis reveals how divergent clinical and commercial vectors interact to shape investment priorities and patient pathways. Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy. The Chemotherapy is further studied across Pemetrexed Combinations and Platinum Monotherapy. The Immunotherapy is further studied across Ctla-4 Inhibitors and Pd-1 Inhibitors. The Targeted Therapy is further studied across Egfr Inhibitors, Mesothelin Targeted Agents, and Vegf Inhibitors. Understanding these modality distinctions clarifies where incremental innovation will emerge and which clinical cohorts may derive disproportionate benefit from novel combinations.

Based on Drug Class, market is studied across Antifolates, Immune Checkpoint Inhibitors, Kinase Inhibitors, Monoclonal Antibodies, and Platinum Compounds. The Immune Checkpoint Inhibitors is further studied across Ctla-4 Inhibitors, Pd-1 Inhibitors, and Pd-l1 Inhibitors. This drug-class perspective highlights the scientific rationale guiding pipeline prioritization and illuminates the mechanisms most amenable to durable responses and tolerability improvements. Based on Line Of Therapy, market is studied across First Line, Second Line, and Third Line And Beyond, which frames strategic decisions around label positioning, comparator selection, and sequencing studies.

Based on Route Of Administration, market is studied across Intraperitoneal, Intravenous, and Oral, a classification that influences patient convenience, administration settings, and payer reimbursement policies. Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, which defines the distribution channels, purchasing dynamics, and service-line implications for adoption. By synthesizing these segmentation lenses, stakeholders can prioritize development paths that align with clinical unmet need, operational feasibility, and payer acceptability while anticipating where differential adoption will occur across care settings.

Regional dynamics and strategic opportunities across the Americas, Europe Middle East & Africa, and Asia-Pacific, highlighting differences in clinical practice, reimbursement frameworks, supply resilience, and collaborative research models

Regional nuances exert material influence on research collaboration, clinical implementation, and commercial strategy. In the Americas, established centers of excellence and integrated care networks facilitate rapid translation of clinical trial findings into practice, but diverse payer landscapes necessitate nuanced value demonstration for broad adoption. In contrast, Europe, Middle East & Africa presents heterogeneous regulatory and reimbursement environments, where centralized approvals often coexist with country-level access variability, creating both opportunities for pan-regional initiatives and challenges for consistent roll-out.

Meanwhile, Asia-Pacific is characterized by accelerating clinical research capacity, expanding biotech innovation, and variable reimbursement maturity across countries. Greater investment in regional manufacturing and localized clinical development is reshaping how global programs are designed and executed. Across all regions, differences in diagnostic infrastructure, pathology expertise, and provider training influence the speed at which novel therapies can be integrated into routine care.

Consequently, sponsors and health system leaders must calibrate regional strategies that account for these differences. Cross-regional collaboration around harmonized protocols, targeted real-world evidence collection, and capacity building in diagnostics can reduce time-to-adoption and improve equity in access. Strategic partnerships that leverage regional strengths while addressing local barriers will be critical for scaling impactful therapies and ensuring that improvements in clinical outcomes reach diverse patient populations.

Key company-level insights that spotlight competitive positioning, pipeline differentiation, strategic partnerships, manufacturing capabilities, and commercialization tactics driving innovation across mesothelioma treatment portfolios

Company-level dynamics within the mesothelioma space are defined by how organizations align pipeline innovation with manufacturing capacity, regulatory strategy, and commercial execution. Leaders differentiate through proprietary mechanisms of action, meaningful biomarker programs, and an ability to generate compelling clinical narratives supported by robust safety and efficacy profiles. Mid-size innovators often pursue nimble combination strategies or niche indications, while larger firms leverage scale to support late-stage development and complex global submissions.

Strategic partnerships and licensing arrangements remain central to accelerating clinical development and broadening geographic reach. Companies that structure collaborations with academic centers and contract research organizations to access specialized surgical techniques or unique patient cohorts can de-risk development and enhance evidentiary depth. Manufacturing competence, including capabilities for complex biologics or targeted agent production, increasingly informs partner selection and commercial readiness.

Commercial differentiation also depends on the ability to engage payers early, present clear value propositions grounded in patient-relevant outcomes, and implement creative contracting approaches when warranted. Organizations that invest in post-approval evidence generation, real-world data initiatives, and provider education are better positioned to drive adoption in constrained access environments. Ultimately, company success will hinge on integrated strategies that connect scientific novelty with pragmatic execution across development, regulation, manufacturing, and market access.

Actionable executive recommendations for industry leaders to accelerate therapeutic innovation, optimize market access strategies, strengthen payer and provider engagement, and build resilient supply and R&D operations

Industry leaders should align near-term operational choices with long-term strategic goals to accelerate meaningful advances in mesothelioma care. First, prioritize biomarker-driven development and incorporate translational endpoints in early-stage trials so that later-phase programs target responsive populations and reduce development attrition. Second, design adaptive trial architectures and platform studies to evaluate combinations efficiently, enabling faster identification of synergistic regimens while conserving patient and financial resources.

Third, strengthen supply chain resilience through supplier diversification, strategic onshoring where feasible, and long-term procurement agreements to mitigate exposure to trade policy shocks. Fourth, engage payers and HTA bodies early to establish evidence plans that address comparative effectiveness, quality-of-life metrics, and budget impact considerations, thereby smoothing the path to reimbursement. Fifth, invest in diagnostics and provider education to ensure that molecular stratification and referral pathways are in place when new therapies become available.

Finally, foster multi-stakeholder partnerships that bring together academic centers, patient advocacy groups, and commercial partners to co-create trial designs, patient support programs, and access initiatives. By integrating scientific rigor with pragmatic commercialization planning and stakeholder engagement, organizations can improve the probability of clinical and market success while enhancing patient access and outcomes.

Transparent research methodology outlining data collection approaches, analytic frameworks, expert advisory engagements, validation protocols, and limitations used to synthesize clinical, regulatory, and commercial insights

The research approach combines primary expert engagement, targeted literature synthesis, and structured analytic frameworks to ensure robust, defensible insights. Subject-matter experts spanning clinical oncology, pathology, regulatory affairs, and supply chain management were consulted to validate assumptions, interpret emerging clinical data, and surface operational implications. Peer-reviewed literature, regulatory guidance documents, and conference proceedings provided the clinical and scientific foundation for therapeutic and diagnostic trends.

Analytic processes included thematic synthesis of clinical trial designs, comparative assessment of mechanism-of-action portfolios, and qualitative evaluation of regional regulatory and reimbursement environments. Validation steps involved cross-referencing expert feedback with public regulatory decisions and clinical practice guidance to ensure coherence and minimize bias. Limitations were explicitly recognized, including variability in regional data availability, heterogeneity in real-world evidence maturity, and the evolving nature of late-breaking clinical findings.

Where data gaps existed, the methodology emphasized transparency about assumptions and recommended areas for follow-up research. The combined approach ensures that conclusions are grounded in multidisciplinary evidence while remaining actionable for commercial, clinical, and policy stakeholders seeking to navigate a rapidly changing mesothelioma landscape.

A decisive concluding synthesis that distills strategic inflection points, stakeholder obligations, policy considerations, and forward-looking priorities necessary to improve patient outcomes and therapeutic progress

The synthesis underscores a clear imperative: progress in mesothelioma will require harmonized advances across diagnostics, therapeutic innovation, and access pathways. Scientific progress in immuno-oncology and targeted agents offers real promise, but durable improvements in patient outcomes depend on precise patient selection, rigorous evidence generation, and the ability to translate trial findings into routine clinical practice. Stakeholders must therefore coordinate across development, regulatory, and payer domains to align incentives and evidence requirements.

Operational readiness, including manufacturing resilience and regional implementation capacity, is equally important to ensure that therapeutic advances are available to patients when approvals occur. In parallel, continued investment in biomarker development, translational research, and pragmatic trial designs will enable more efficient identification of impactful treatments. The combined focus on scientific rigor, commercial pragmatism, and collaborative problem-solving positions the field to deliver measurable improvements in care and to reduce barriers that currently limit patient access to promising therapies.

In closing, the path forward demands strategic alignment, sustained investment, and an unwavering commitment to patient-centered evidence that supports adoption and equitable access across care settings and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Novel immunotherapy combinations showing improved survival in malignant mesothelioma patients
  • 5.2. Adoption of mesothelin-targeted antibody-drug conjugates in late-stage clinical trials
  • 5.3. Emergence of personalized treatment strategies leveraging genomic profiling in mesothelioma
  • 5.4. Increasing utilization of dual checkpoint inhibitors in frontline mesothelioma treatment regimens
  • 5.5. Growing pipeline of CAR T cell therapies targeting mesothelin for mesothelioma management
  • 5.6. Rising focus on early diagnostic biomarkers and liquid biopsy technology in mesothelioma
  • 5.7. Advances in photodynamic therapy applications for unresectable malignant mesothelioma
  • 5.8. Development of multimodal treatment protocols integrating surgery radiation and systemic therapy
  • 5.9. Heightened awareness of asbestos exposure litigation impact on mesothelioma patient enrollment
  • 5.10. Expansion of real world evidence data sets informing treatment guidelines and reimbursement

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Malignant Mesothelioma Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Pemetrexed Combinations
    • 8.1.2. Platinum Monotherapy
  • 8.2. Immunotherapy
    • 8.2.1. Ctla-4 Inhibitors
    • 8.2.2. Pd-1 Inhibitors
  • 8.3. Radiotherapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Egfr Inhibitors
    • 8.5.2. Mesothelin Targeted Agents
    • 8.5.3. Vegf Inhibitors

9. Malignant Mesothelioma Market, by Drug Class

  • 9.1. Antifolates
  • 9.2. Immune Checkpoint Inhibitors
    • 9.2.1. Ctla-4 Inhibitors
    • 9.2.2. Pd-1 Inhibitors
    • 9.2.3. Pd-l1 Inhibitors
  • 9.3. Kinase Inhibitors
  • 9.4. Monoclonal Antibodies
  • 9.5. Platinum Compounds

10. Malignant Mesothelioma Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Malignant Mesothelioma Market, by Route Of Administration

  • 11.1. Intraperitoneal
  • 11.2. Intravenous
  • 11.3. Oral

12. Malignant Mesothelioma Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Malignant Mesothelioma Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Malignant Mesothelioma Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Malignant Mesothelioma Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Bristol-Myers Squibb Company
    • 16.3.2. Eli Lilly and Company
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. F. Hoffmann-La Roche Ltd.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Johnson & Johnson
    • 16.3.8. Novartis AG
    • 16.3.9. Takeda Pharmaceutical Company Limited
    • 16.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MALIGNANT MESOTHELIOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)

TAB